Core Viewpoint - Inventiva S.A. Sponsored ADR (IVA) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Inventiva indicates that for the fiscal year ending December 2025, the company is expected to earn -$1.30 per share, reflecting a 61% change from the previous year's reported number [8]. - Over the past three months, the Zacks Consensus Estimate for Inventiva has increased by 20.7%, indicating a positive trend in earnings estimates [8]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][4]. - The system classifies stocks into five groups, with Zacks Rank 1 (Strong Buy) stocks generating an average annual return of +25% since 1988, showcasing its effectiveness [7]. - The upgrade of Inventiva to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Group 1 - The core focus of Inventiva is the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) [4] - Inventiva will participate in two investor conferences in June 2025, including the Jefferies Global Healthcare Conference and the UBS Spring Biotech Conference [2][3] - Frédéric Cren, CEO of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 [2] Group 2 - Inventiva is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for MASH treatment [4] - The company is publicly listed on Euronext Paris and NASDAQ, with the ticker symbol IVA [5]

Core Insights - Inventiva reported a decrease in cash and cash equivalents to €67.9 million as of March 31, 2025, down from €96.6 million at the end of 2024, primarily due to cash used in operating activities for the lanifibranor development program [2][3] - The company anticipates that its current cash resources, along with gross proceeds of €115.6 million from structured financing and a $10 million milestone payment from Chia Tai Tianqing Pharmaceutical Group, will fund operations until the end of Q3 2026 [3] - Inventiva did not recognize any revenues in Q1 2025, consistent with Q1 2024 [5] Financial Results - Cash and cash equivalents as of March 31, 2025: €67.9 million, a decrease of €28.7 million from €96.6 million on December 31, 2024 [2] - Gross proceeds from structured financing: €115.6 million, with net proceeds of €108.5 million [3] - Anticipated milestone payment from CTTQ: $10 million [3] Research and Development Updates - The company completed enrollment for its pivotal Phase 3 clinical trial, NATiV3, evaluating lanifibranor in patients with MASH [10] - The company initiated a clinical development program for lanifibranor in Japan with the first participant dosed in a Phase 1 trial [10] - Recent publications include findings on non-invasive biomarker signatures and improvements in portal hypertension with lanifibranor treatment [10] Future Outlook - The company plans to raise additional funds for the long-term development and commercialization of lanifibranor through public offerings, private placements, and strategic partnerships [4] - Topline results from the NATiV3 trial are expected in the second half of 2026 [8]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting [1][12] - The meeting took place on May 22, 2025, in Paris, chaired by CEO Frédéric Cren [2] - All resolutions were adopted except for the 33rd resolution, which was negatively recommended by the Board of Directors [3] Voting Results - The shareholders present included 245 participants, representing a total of 90,772,892 shares and 102,984,957 votes, achieving a quorum of 65.264% [5] - Ordinary resolutions were overwhelmingly adopted, with the first resolution receiving 99.98% approval [6][10] - The 33rd resolution, which would have allowed the Board to decide on share capital increases for a company savings plan, was rejected with 90.58% against [10][11] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other unmet medical needs [12][13] - The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial for MASH treatment [12]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][11] - The Combined Shareholders' Meeting took place on May 22, 2025, where all resolutions were adopted except for one [2][3] - The compensation policy for corporate officers was approved as presented in the 2024 Universal Registration Document [4] Voting Results - A total of 245 shareholders participated in the voting, representing 90,772,892 shares, which is 65.264% of the voting rights [5][7] - The majority of ordinary resolutions were adopted with over 99% approval, while the only rejected resolution was the 33rd, which aimed to empower the Board of Directors for share capital increases [3][10] - The voting results showed a high level of shareholder engagement, with a quorum of 65.264% achieved [5][10] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on unmet medical needs in liver diseases [11][12] - The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial for MASH [11]

Core Viewpoint - The company Inventiva has approved a share repurchase program aimed at enhancing market liquidity, with a maximum purchase limit of 10% of its capital over the next 18 months [1][4]. Group 1: Share Repurchase Program - The share repurchase program was approved during the Ordinary General Meeting on May 22, 2025, with the primary objective of animating the market under a liquidity agreement [1][2]. - The maximum number of shares that can be acquired is 13,869,673, considering the 45,454 shares already held in treasury as of May 19, 2025 [4]. - The maximum price per share for the repurchase is set at 40 euros [4]. Group 2: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH and other diseases with significant unmet medical needs [2]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the pivotal Phase 3 clinical trial for treating adult patients with MASH [2]. Group 3: Market Information - Inventiva is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States [3]. - The company has a total of 13,915,127 shares in its capital structure as of May 19, 2025 [4].

Core Viewpoint - Inventiva has successfully completed the enrollment of the Phase 3 NATiV3 study for lanifibranor in MASH and has initiated the second tranche of its structured financing, raising €115.6 million in gross proceeds to support the drug's development [1][2][4]. Financing Details - The second tranche of structured financing amounts to €115.6 million gross (net proceeds of €108.5 million) [1][4]. - The financing was led by existing investors from the first tranche, including New Enterprise Associates, BVF Partners LP, and Samsara BioCapital [3]. Use of Proceeds - The net proceeds from the T2 Transaction will primarily be used to finance the development of lanifibranor in MASH, particularly the continuation of the NATiV3 Phase 3 clinical trial [4]. Financial Position - As of December 31, 2024, the company's cash and cash equivalents were €96.6 million, which was projected to cover operational needs until mid-Q3 2025 [5]. - Following the T2 Transaction, the company estimates sufficient net working capital to meet obligations for the next 12 months, extending financing capabilities until the end of Q3 2026 [6]. Future Funding Needs - The company will require additional funding to achieve long-term objectives for lanifibranor's development and potential commercialization through public offerings, private placements, or strategic partnerships [7]. Transaction Characteristics - The T2 Transaction involves the issuance of 42,488,883 new shares at a subscription price of €1.35 per share, with attached warrants [9][12]. - The Board confirmed that all conditions for the issuance of the second tranche have been satisfied, including the completion of enrollment in the NATiV3 study [10][11]. Shareholder Impact - The issuance of new shares and warrants will dilute existing shareholders, with significant changes in ownership percentages expected post-transaction [23][25][29].

Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of Ma ...

Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: www.inventivapharma.com DateNumber of shares outstandingTotal voting rights,gross (1)Total voting rights,net (2)April 11, 202595,662,391108,635,435108,574,827 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all share ...

► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► The biomarker signatures suggested strong predictive accuracy, with AUROC values above 0.80 that may indicate high reliabilit ...